Sentinel lymph nodes in melanoma patients: Evaluating the evidence

Oncology

Volumn 71, Issue 5-6, 2007, Pages 460-462

  De Giorgi, Vincenzo ^a   Leporatti, Genny ^a   Massi, Daniela ^a   Lo Russo, Giulia ^a   Sestini, Serena ^a   Papi, Federica ^a   Dini, Mario ^a   Lotti, Torello ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE COURSE; DISEASE FREE SURVIVAL; EVIDENCE BASED MEDICINE; HUMAN; LETTER; LYMPHADENECTOMY; MELANOMA; PRIORITY JOURNAL; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; TREATMENT INDICATION;

DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HUMANS; LYMPHATIC METASTASIS; MELANOMA; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY;

EID: 35348832559     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000108577     Document Type: Letter

References (24)

1. Balch CM, Soong SJ, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-3634.
2. Balch CM, Buzaid AC, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648.
3. Thompson JF, Scolyer RA, Kefford RF: Cutaneous melanoma. Lancet 2005;365:687-701.
4. Thomas JM: Caution with sentinel node biopsy in melanoma. Br J Surg 2006;93:129-130.
5. Morton DL, Wen DR, Wong JH, et al: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-399.
6. Thomas JM: Time to re-evaluate sentinel node biopsy in melanoma post-multicenter selective lymphadenectomy trial. J Clin Oncol 2005;23:9443-9444.
7. Gershenwald JE, Thomson W, Mansfield PF, et al: Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-983.
8. Starz H, Siedlecki K, Balda BR: Sentinel lymphonodectomy and S-classification: a successful strategy for better prediction and improvement of outcome of melanoma. Ann Surg Oncol 2004(suppl 3);11:162S-168S.
9. Carlson GW, Murray DR, Lyles RH, et al: The amount of metastatic melanoma in a sentinel lymph node: does it have prognostic significance? Ann Surg Oncol 2003;10:575-581.
10. Spanknebel K, Coit DG, Bieligk SC, et al: Characterization of micrometastastic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol 2005;29:305-317.
11. Roka F, Kittler H, Cauzig P, et al: Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis. Br J Cancer 2005;92:662-666.
12. Vuylsteke RJ, Van Leeuwen PAM, Statius Muller MG, et al: Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long term follow-up results. J Clin Oncol 2003;21:1057-1065.
13. Gadd MA, Cosimi BA, Yu B, et al: Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg 1999;134:381-387.
14. Nowecki ZI, Rutkowski P, Guttmejer AN, Ruka W: Sentinel lymph node biopsy in melanoma patients with clinically negative regional lymph nodes - one institution's experience. Melanoma Res 2003;13:35-43.
15. Nieweg OE, Estourgie SH: What is a sentinel node and what is a false-negative sentinel node? Ann Surg Oncol 2004;11(3 suppl):169S-173S.
16. Leiter U, Friedegund M, Schittek M, Garbe C: The natural course of cutaneous melanoma. J Surg Oncol 2004;86:172-178.
17. Meier F, Will S, Ellwanger U, et al: Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002;147:62-70.
18. American Society of Clinical Oncology. Meetings and Education: Virtual Meeting. Interim Results of the Multicenter Selective Lymphadenectomy Trial (MSLT-1) in Clinical Stage I Melanoma. http://www.asco.org/ac/1,1003,_12-002640- 00_18-0034-00_19-0031917,00.asp (accessed Feb 2006).
19. Morton DL, Thompson JF, Cochran AJ, et al: Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:1307-1317.
20. Morton DL, Thompson JF, Cochran AJ, et al: Interim results of the Multicenter Selective Lymphadenectomy Trial (MSLT-1) in clinical stage 1 melanoma (abstract). J Clin Oncol 2005;23(suppl):S710.
21. Hayes AJ, Thomas JM: Recurrence-free survival after sentinel node biopsy in melanoma? Br J Dermatol 2006;155:631-632.
22. Thomas JM, Clark MA: Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma. Eur J Surg Oncol 2004;30:686-691.
23. Borgstein PJ, Meijer S, van Diest PJ: Are locoregional cutaneous metastases in melanoma predictable? Ann Surg Oncol 1999;6:315-321.
24. de Vries M, Jager PL, Suurmeijer AJH, et al: Schildwachtklierbiopsie bij het melanoom: Prognostische betekenis en nadelen bij 300 patienten. Ned Tijdschr Geneeskd 2005;149:1845-1851.